NXGL · Nexgel, Inc.
$0.44
+0.01 (+2.09%)
At close · Jul 24
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$4.01M
Shares
9.13M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$11.42M
+31.5%
FY2025
Net Income
-$3M
+8.6%
FY2025
Gross Margin
39.48%
+7.8pp
FY2025
Operating Margin
-29.35%
+11.6pp
FY2025
Diluted EPS
-$0.38
+24%
FY2025
Operating Cash Flow
-$1.31M
+66.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $11.27M | $11.42MG | $8.69M | $4.09M | $2.05M | $1.55M | $674K | $717K | |
| $6.88M | $6.91M | $5.94M | $3.47M | $1.79M | $1.54M | $965K | $854K | |
| $4.38M | $4.51M | $2.75M | $619K | $256K | $9000 | -$291K | -$137K | |
| — | 39.48% | 31.63% | 15.14% | 12.5% | 0.58% | -43.18% | -19.11% | |
| — | $2000 | $78K | $103K | $367K | $31K | — | — | |
| $7.91M | $7.86M | $6.22M | $3.99M | $3.24M | $2.55M | $1.97M | $1.79M | |
| — | $126K | $119K | $94K | — | — | — | — | |
| — | $450K | $436K | $226K | $112K | $113K | $50K | $67K | |
| $7.92M | $7.86M | $6.3M | $4.1M | $3.6M | $2.58M | $1.97M | $1.79M | |
| -$3.53M | -$3.35M | -$3.55M | -$3.48M | -$3.35M | -$2.57M | -$2.26M | -$1.92M | |
| — | -29.35% | -40.91% | -85.03% | -163.48% | -165.7% | -335.31% | -268.34% | |
| — | -$2.9M | -$3.12M | -$3.25M | -$3.24M | -$2.46M | -$2.21M | -$1.86M | |
| — | $34K | $81K | $15K | — | — | — | — | |
| $447K | $459K | $91K | $289K | -$1.4M | -$1.74M | -$4000 | — | |
| -$3.09M | -$2.89M | -$3.46M | -$3.19M | — | — | — | — | |
| — | — | — | — | $0 | $0 | $0 | — | |
| -$3.24M | -$3M | -$3.28M | -$3.16M | -$4.75M | -$4.31M | -$2.26M | -$1.92M | |
| — | -26.27% | -37.76% | -77.21% | -231.74% | -277.89% | -335.91% | -268.2% | |
| $129K | $107K | -$182K | -$31K | — | — | — | — | |
| USD/shares | — | -$0.38 | -$0.50 | -$0.56 | -$0.85 | -$1.45 | -$0.03 | -$0.14 |
| USD/shares | — | -$0.38 | -$0.50 | -$0.56 | — | -$1.45 | -$0.03 | -$0.14 |
| shares | — | 7.85M | 6.51M | 5.67M | 5.57M | 2.98M | 78.9M | 13.57M |
| shares | — | 7.85M | 6.51M | 5.67M | — | 2.98M | 78.9M | 13.57M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Instruments & Supplies median 2.10×
EV/EBIT
—
Medical Instruments & Supplies median 28.57×
P/E (TTM)
—
Medical Instruments & Supplies median 35.14×